Antithrombotic	B:C0243095
activity	I:C0243095
of	O
Batroxase	B:C4278231
,	O
a	O
metalloprotease	B:C0025543
from	O
Bothrops	B:C4033446
atrox	I:C4033446
venom	I:C4033446
,	O
in	O
a	O
model	B:C0599779
of	O
venous	B:C0042487
thrombosis	I:C0042487
Snake	B:C0037380
venoms	I:C0037380
are	O
great	O
sources	O
of	O
bioactive	O
molecules	O
,	O
which	O
may	O
be	O
used	O
as	O
models	B:C3161035
for	O
new	O
drugs	B:C0013227
.	O

Toxins	B:C0040549
that	O
interfere	O
in	O
hemostasis	B:C0005779
have	O
received	O
considerable	O
attention	O
over	O
the	O
years	O
.	O

This	O
study	B:C2603343
aimed	O
at	O
the	O
evaluation	O
of	O
the	O
antithrombotic	B:C0243095
activity	I:C0243095
of	O
Batroxase	B:C4278231
,	O
a	O
P	B:C0025543
-	I:C0025543
I	I:C0025543
metalloprotease	I:C0025543
from	O
Bothrops	B:C4033446
atrox	I:C4033446
venom	I:C4033446
,	O
in	O
an	O
animal	B:C0599779
model	I:C0599779
of	O
venous	B:C0042487
thrombosis	I:C0042487
.	O

The	O
antithrombotic	B:C0243095
activity	I:C0243095
of	O
Batroxase	B:C4278231
was	O
tested	O
in	B:C1515655
vivo	I:C1515655
in	O
a	O
model	B:C0599779
based	O
on	O
two	O
factors	O
of	O
the	O
Virchow	B:C0282574
's	I:C0282574
Triad	I:C0282574
:	O
blood	B:C0232338
flow	I:C0232338
alterations	O
(	O
partial	B:C0333183
stenosis	I:C0333183
of	O
the	O
inferior	B:C0042458
vena	I:C0042458
cava	I:C0042458
)	O
,	O
and	O
vessel	B:C0229962
wall	I:C0229962
injury	B:C0178314
(	O
10	O
%	O
ferric	B:C0060229
chloride	I:C0060229
for	O
5	O
min	O
)	O
,	O
in	O
comparison	O
with	O
sodium	B:C0037513
heparin	I:C0037513
(	O
positive	O
control	O
)	O
and	O
saline	O
(	O
negative	O
control	O
)	O
.	O

Bleeding	B:C0550585
/	O
clotting	B:C2266672
time	I:C2266672
was	O
assessed	O
by	O
a	O
tail	O
bleeding	B:C0019080
assay	I:C0019080
.	O

The	O
immunogenicity	B:C1148560
of	O
Batroxase	B:C4278231
was	O
also	O
analyzed	O
.	O

Batroxase	B:C4278231
(	O
12mg/kg	O
)	O
reduced	O
thrombus	B:C0243095
formation	I:C0243095
in	O
81	O
%	O
,	O
similarly	O
to	O
heparin	B:C0019134
(	O
100U	O
/	O
kg	O
)	O
,	O
which	O
reduced	O
it	O
in	O
85	O
%	O
in	O
comparison	O
with	O
the	O
saline	O
group	O
.	O

Both	O
Batroxase	B:C4278231
and	O
heparin	B:C0019134
increased	O
bleeding	B:C0550585
/	O
clotting	B:C2266672
time	I:C2266672
in	O
approximately	O
3	O
fold	O
.	O

Immunizations	B:C0020971
of	O
rabbits	B:C3887509
with	O
Batroxase	B:C4278231
do	O
not	O
result	O
in	O
detectable	O
levels	O
of	O
antibodies	B:C0003241
against	O
this	O
metalloprotease	B:C0025543
.	O

Batroxase	B:C4278231
presents	O
antithrombotic	B:C0243095
activity	I:C0243095
in	B:C1515655
vivo	I:C1515655
.	O

Moreover	O
,	O
its	O
lack	O
of	O
immunogenicity	B:C1148560
increases	O
the	O
interest	O
on	O
its	O
possible	O
therapeutic	O
potential	O
over	O
thrombogenic	B:C0012634
disorders	I:C0012634
.	O

